Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany's experience after 5 years of licensure.
Vaccine effectiveness (VE) was determined with a case-cohort approach using Cox regression. Cases with confirmed systemic Hib infections in children born from 1 August 2000 to 31 December 2004 were ascertained through two independent nationwide active surveillance systems. A representative cohort of 1303 children born in the same time frame was randomly sampled in a nationwide immunisation survey. Thirty cases were eligible for VE calculation; 19 were unvaccinated and 11 vaccinated with hexavalent vaccines. VE was 68.4% (95% CI: 19.0-87.6) for incomplete primary series and 90.4% (95% CI: 70.6-96.8) for the full primary series. For full immunisation VE was 100.0% (95% CI: 52.7-100.0). Hexavalent vaccines show a high effectiveness against invasive Hib disease in Germany.
Kalies
Helen
H
Institute of Social Paediatrics and Adolescent Medicine, Ludwig-Maximilian-University, Munich, Germany. kalies@uni-muenchen.de
Grote
Veit
V
Siedler
Anette
A
Gröndahl
Britta
B
Schmitt
Heinz-Josef
HJ
von Kries
Rüdiger
R
D016022:Case-Control Studies; D002675:Child, Preschool; D015331:Cohort Studies; D005858:Germany / Q000453:epidemiology; D018073:Haemophilus Vaccines / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D008583:Meningitis, Haemophilus / Q000453:epidemiology* / Q000276:immunology* / Q000382:microbiology
D018073:Haemophilus Vaccines